Stock GUD KNIGHT THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Knight Therapeutics Inc.

Equities

GUD

CA4990531069

Pharmaceuticals

Market Closed - Toronto S.E.
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
5.69 CAD -0.52% Intraday chart for Knight Therapeutics Inc. -1.73% +9.63%
Mar. 22 Knight Therapeutics Price Target Raised to $7 at RBC MT
Mar. 21 Knight Therapeutics Reports Fourth Quarter Results MT

Business Summary

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.

Number of employees: 725

Sales per Business

CAD in Million2022Weight2023Weight Delta
Pharmaceutical Products, Consumer Health Products and Medical Devices
100.0 %
294 100.0 % 328 100.0 % +11.80%

Sales per region

CAD in Million2022Weight2023Weight Delta
Brazil
51.3 %
135 45.9 % 168 51.3 % +24.86%
Rest of Latin America
16.8 %
40 13.7 % 55 16.8 % +37.17%
Colombia
13.6 %
46 15.7 % 45 13.6 % -3.24%
Argentina
7.3 %
48 16.4 % 24 7.3 % -49.95%
Canada
6.0 %
11 3.9 % 20 6.0 % +73.39%
Other
5.0 %
13 4.4 % 16 5.0 % +26.27%

Managers

Managers TitleAgeSince
Samira Sakhia CEO
 Chief Executive Officer 55 13-10-31
Jonathan Goodman FOU
 Founder 56 13-10-31
Arvind Utchanah DFI
 Director of Finance/CFO - 16-06-19
Leopoldo Bosano COO
 Chief Operating Officer - -
Monica Percario CTO
 Chief Tech/Sci/R&D Officer - -
Susan Emblem HRO
 Human Resources Officer - 20-09-30
Amal Khouri PRN
 Corporate Officer/Principal - 14-07-31

Members of the board

Members of the board TitleAgeSince
James Gale BRD
 Director/Board Member 74 14-01-05
Jonathan Goodman FOU
 Founder 56 13-10-31
Robert N. Lande BRD
 Director/Board Member 61 12-12-31
Samira Sakhia CEO
 Chief Executive Officer 55 13-10-31
Nicolás Sujoy Spiguel BRD
 Director/Board Member 48 19-12-31
Michael Tremblay BRD
 Director/Board Member 71 18-12-31
Janice Murray BRD
 Director/Board Member 58 19-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 101,186,861 54,193,855 ( 53.56 %) 0 53.56 %

Shareholders

NameEquities%Valuation
Long Zone Holdings, Inc.
21.43 %
21,678,733 21.43 % 85 M $
Gestion de Portefeuille Stratégique Medici, Inc.
12.82 %
12,973,505 12.82 % 51 M $
G2S2 Capital, Inc.
12.61 %
12,760,000 12.61 % 50 M $
Jonathan Goodman
0.8951 %
905,553 0.8951 % 4 M $
COTE 100, Inc.
0.7848 %
794,000 0.7848 % 3 M $
Robert N. Lande
0.2788 %
282,108 0.2788 % 1 M $
Manulife Investment Management Ltd.
0.2708 %
273,983 0.2708 % 1 M $
Samira Sakhia
0.2494 %
252,286 0.2494 % 988 961 $
IA Clarington Investments, Inc.
0.2338 %
236,500 0.2338 % 927 080 $
Dimensional Fund Advisors Ltd.
0.1557 %
157,509 0.1557 % 617 435 $

Holdings

NameEquities%Valuation
60 DEGREES PHARMACEUTICALS, INC.
10.42%
 1,153,897 10.42% 301,167 $

Company contact information

Knight Therapeutics, Inc.

3400 de Maisonneuve West Suite 1055

H3Z 3B8, Montréal

+514-484-4483

http://www.gud-knight.com
address Knight Therapeutics Inc.(GUD)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Specialty & Advanced Pharmaceuticals

Sales per region

Ratings for Knight Therapeutics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.72 CAD
Average target price
6.729 CAD
Spread / Average Target
+17.63%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
KNIGHT THERAPEUTICS INC. Stock Knight Therapeutics Inc.
+9.63% 422M
MERCK KGAA Stock Merck KGaA
+4.16% 70.78B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.65% 9.15B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-17.03% 4.84B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+37.51% 4.22B
YUHAN CORPORATION Stock Yuhan Corporation
+3.92% 3.92B
INDIVIOR PLC Stock Indivior PLC
+18.14% 2.55B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-24.13% 2.26B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.70% 2.24B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+9.09% 1.92B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GUD Stock
  4. Company Knight Therapeutics Inc.